Although these drugs demonstrated effectiveness in improving blood sugar control and promoting weight loss, lawsuits now allege that GLP-1 receptor agonists may also be associated with severe gastrointestinal injuries, optic nerve complications, and other serious adverse health effects
Effective dosing for most users ranges from 0.25mg to 0.5mg daily during loading phases, with underdosing below 0.2mg being the most common cause of perceived non-response
There is increasing research and interest in combination therapies, such as pairing GLP-1 receptor agonists with other metabolic agents, to enhance efficacy as well as support patient adherence
Figure 1 Oligomeric A 40 Induces Free Radical Damage to DNA, Lipids, and Protein Which Could be Attenuated Using GGC To confirm that oligomeric A 40 is cytotoxic to astrocytes via induction of oxidative stress, we monitored the effect of oligomeric A 40 on free radical generation